ASH: ELI LILLY PLOTS 'AMBITIOUS' CANCER PROGRAM AFTER SHARING EARLY BTK DATA

Eli Lilly shared early clinical data on the BTK inhibitor it acquired with Loxo Oncology-and the numbers are strong enough to prompt...

HOPKINS TEAM INVENTS NON-VIRAL SYSTEM FOR GETTING GENE THERAPY INTO CELLS

Noninfectious viruses used to deliver gene therapy can still sometimes touch off dangerous immune responses. A team from Johns Hopkins...

 
 
 

CHUTES & LADDERS-SANOFI STRATEGY CHIEF MANSURI SET TO STEP AWAY

Mansuri will step down from Sanofi strategy role; Ratliff takes lead at AMRI after brief LabCorp stint; Caraway taps Williams for chief...

FDA KNOCKS DOWN ENZYVANT CANDIDATE ON MANUFACTURING CONCERNS AFTER PLANT INSPECTION

Privately held biotech Enzyvant was hoping its first shot at an FDA approval with a rare immunodeficiency disease candidate would come...

 
 
 

FDA HITS IPSEN'S $1B DRUG WITH CLINICAL HOLD OVER SAFETY SIGNAL

The FDA has placed two trials of palovarotene on partial clinical hold eight months after Ipsen gained the drug in its $1 billion takeover...

BIOGEN'S RORSCHACH READOUT CONTINUES AS DETAILED ALZHEIMER'S DATA DIVIDE EXPERTS

Biogen has shared the detailed data on aducanumab that it hopes will secure FDA approval in Alzheimer's disease. The Clinical Trials...

 
 
 

HOW WORMS REVEALED A KEY PROTEIN IN INSULIN SYNTHESIS AND DIABETES

By studying the nematode Caenorhabditis elegans, scientists from Vanderbilt University and the University of Michigan have identified...

AURINIA SOARS AS PHASE 3 LUPUS STUDY HITS PRIMARY ENDPOINT

A phase 3 trial of Aurinia Pharmaceuticals' voclosporin in lupus nephritis has hit its primary endpoint, causing the company's share...

 
 
 

SAGE CRUSHED BY MOUNTAIN AS PHASE 3 DEPRESSION DATA FALL SHORT

Sage Therapeutics' key phase 3 trial in major depressive disorder has missed its primary endpoint. The failure of SAGE-217 to beat...

TROUBLED IMMUNOMEDICS TRIES AGAIN AT FDA AFTER REJECTION

Immunomedics has had a long and troubled road in the past few years that has included losing much of its C-suite after an FDA rejection,...

 
 
 

TURNING MERCK'S COPD DRUG AGAINST RESISTANT PROSTATE CANCER

Aggressive castration-resistant prostate cancer can persist after treatment with standard-of-care hormone therapies targeting the androgen...

OMEROS HITS ENDPOINT IN PIVOTAL STEM CELL TRANSPLANT STUDY

A pivotal trial of Omeros' narsoplimab in hematopoietic stem cell transplant patients has hit its primary endpoint. Omeros expects...

 
 
 

PFIZER VENTURES HELPS GAMMA DELTA PLAYER IMCHECK TO $53M ROUND

Pfizer Ventures has co-led a $53 million series B investment in ImCheck, a developer of antibodies focused on gamma delta T cells....

ARDELYX'S KIDNEY DISEASE DRUG HITS GOAL IN PHASE 3, TEEING IT UP FOR FDA FILING

A phase 3 trial of Ardelyx's tenapanor in chronic kidney disease patients on dialysis has met its primary endpoint. The success comes...

 
 
 

BRII BIOSCIENCES NABS ICON, GSK VETERAN TO LEAD NEW FOCUS ON NEUROSCIENCE

U.S.-China biotech Brii Biosciences is pushing out into new territory with a new hire alongside a focus on a new R&D area.

'POSITIVE SURPRISE' FOR BIOGEN IN LUPUS, BUT ALL EYES ON CTAD DATA THIS WEEK

Biogen is joining AstraZeneca on a strong positive for its lupus candidates as the pair face going head-to-head on the market.

 
 
 

ASTELLAS INKS $3B AUDENTES BUYOUT TO EXPAND IN GENE THERAPY

Astellas Pharma is set to buy Audentes Therapeutics for $3 billion. The deal will enable Astellas to set up a new genetic regulation...

CYRUS, THE BROAD TEAM UP TO MAKE IN VIVO CRISPR USE SAFER

Cyrus Biotechnology has teamed up with the Broad Institute to optimize CRISPR for use in humans. Feng Zhang, who had a hand in developing...

 
 
 

ANALYST: BIOGEN'S ADUCANUMAB IS NOT GETTING APPROVED ABSENT A DEUS EX MACHINA

Baird analyst Brian Skorney has dismissed the chances of Biogen winning approval for its Alzheimer's disease drug aducanumab. Skorney's...

TREATING MULTIPLE SCLEROSIS WITH THE HELP OF THE GUT MICROBIOME

A team at Brigham and Women's Hospital discovered a microRNA in the microbiome that increases when multiple sclerosis peaks. When they...

 
 
 



World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

IAmScience Mannie Liscum

IAmScience Mannie Liscum

For Mannie Liscum, thinking is a privilege, and his job gives him the chance to be fascinated by human's capacity to conceptualize and learn new things. “It's my goal to use as... Read more ...

New Sanofi CEO Hudson adds next-gen cancer drug tech to the R&D quest...

When Paul Hudson lays out his R&D vision for Sanofi tomorrow, he will have a new slate of interleukin therapies and a synthetic biology platform to boast about. The French... Read more ...

AveXis Inc.: Senior Scientific Training Specialist - cGMP Gene Therapy

AveXis Inc.: OverviewReady to join a team committed to developing and commercializing gene therapies for patients and families devastated by rare neurological gene San Diego... Read more ...

Process Engineer I - Genentech - Oceanside, CA

Focus will be on one or more areas such as design, implementation and/or start-up of new and/or existing facilities with respect to process and/or clean utility...From... Read more ...

Pineoblastoma segregates into molecular sub-groups with distinct...

Abstract Pineoblastomas are rare, aggressive pediatric brain tumors of the pineal gland with modest overall survival despite intensive therapy. We sought to define the clinical... Read more ...

The majority of A-to-I RNA editing is not required for mammalian homeostasis

Abstract Background Adenosine-to-inosine RNA editing, mediated by ADAR1 and ADAR2, occurs at tens of thousands to millions of sites across mammalian transcriptomes. A-to-I... Read more ...

CRISPR System: A High-throughput Toolbox for Research and Treatment of...

Abstract In recent years, the innovation of gene-editing tools such as the CRISPR/Cas9 system improves the translational gap of treatments mediated by gene therapy. The... Read more ...

Exploration of cryptic organic photosensitive compound as Zincphyrin IV in...

Abstract Zincphyrin IV is a potential organic photosensitizer which is of significant interest for applications in biomedicine, materials science, agriculture , and chemistry... Read more ...

Three transcriptional regulators positively regulate the biosynthesis of...

Abstract Polycyclic tetramate macrolactams are a widely distributed class of structurally complex natural products, and most of them exhibit multiple biological activities... Read more ...

Faint gray bands in Drosophila melanogaster polytene chromosomes are formed...

Abstract In Drosophila melanogaster , the chromatin of interphase polytene chromosomes appears as alternating decondensed interbands and dense black or thin gray bands... Read more ...